Pneumococcal Conjugate Vaccine (10-Valent)

(noo moe KOK al KON ju gate vak SEEN, ten vay lent)

Promotes active immunization against invasive disease caused by S. pneumoniae capsular serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, all which are individually conjugated to a carrier protein (protein D, tetanus toxoid, or diphtheria toxoid); the aluminum salt, a mineral adjuvant, enhances the antibody response.

Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy. Consider therapy modification

Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation. Consider therapy modification

Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Exceptions: Cytarabine (Liposomal). Consider therapy modification

Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated). Monitor therapy

*Incidence not specifically defined, but reported in the range of 1% to 10%.

>10%:

Central nervous system: Irritability (51% to 66%), drowsiness (33% to 58%)

Gastrointestinal: Anorexia (17% to 31%)

Local: Pain at injection site (23% to 57%), erythema at injection site (38% to 53%), swelling at injection site (28% to 37%)

Miscellaneous: Fever (rectal; ≥38°C ages <2 years: 26% to 37%; >39°C ages <2 years: 2% to 3%; >39°C ages 2 to 5 years: <1%; >40°C ages <2 years: <1%; ≥38°C ages 2 to 5 years*)

1% to 10%:

Local: Induration at injection site

<1% (Limited to important or life-threatening): Apnea (in premature infants ≤28 weeks gestation), bleeding at injection site, crying (abnormal), diarrhea, hematoma at injection site, hypersensitivity reaction (allergic dermatitis, atopic dermatitis, eczema), injection site nodule, seizure (febrile and nonfebrile), skin rash, urticaria, vomiting